Feedback PLC Award of Pilot Funding (2189X)
2023年12月19日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMFDBK
RNS Number : 2189X
Feedback PLC
19 December 2023
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR"). With the publication of this announcement,
this information is now considered to be in the public domain.
Feedback plc
Feedback awarded pilot funding to undertake further CDC pathway
development
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
clinical infrastructure specialist, announces it is conducting a
series of pilot programmes of Community Diagnostic Centre ("CDC")
care pathways funded by a combined award of GBP300,000. The Company
has directly contracted with the individual NHS organisations
hosting the pilot sites utilising funds locally disbursed for this
purpose under NHS England's ("NHSE"), Community Diagnostic Centre
Programme.
These pilots, which will initially run until 31 March 2024, will
build on Feedback's pilot contract for the Sussex ICS with QVH and
aim to further demonstrate the impact of a pathway approach on CDC
utilisation and wider patient wait times. The pilot implementations
will also facilitate GP Direct access into CDC diagnostic
services.
Two pilot sites are participating in the programme - Amersham
CDC in Buckinghamshire and a pan regional pilot across
Buckinghamshire, Oxfordshire and Berkshire ICS (BOB ICS), looking
at multiple service lines and mutual aid delivery models for
sharing workforce capacity at a regional basis through the Bleepa
platform.
The evidence generated by these pilots will build the case for
subsequent funding of a pathway approach to CDC delivery in
subsequent financial years and NHSE will be closely monitoring the
pilot outcome data as the programme rolls out in order to inform
forward planning.
Dr Tom Oakley, CEO of Feedback plc said: "We are delighted to
have the opportunity to further build the evidence base for a
pathway approach to CDCs using Bleepa. This will generate the
results back into the clinical pathway, under the noses of decision
makers and enable them to facilitate a robust clinical dialogue to
transform results into care decisions.
"Bleepa has already demonstrated a 69% reduction in wait times
through the power of asynchronous communication and a pathway
approach with Queen Victoria Hospital in Sussex. This is the sort
of impact data that will support the NHS to address elective care
backlogs and to help ease winter pressures. It is a privilege to
work with a number of new NHS partners to help them deliver this
impact for their patients and staff.
"The team very much look forward to commencing these pilots and
further strengthening our relationship with the NHS, which provides
funding for a number of vanguard projects to champion the adoption
and use of digital technology and innovation in care pathways."
--Ends--
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited
(NOMAD and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd; Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Nick Rome/Joe Walker 07748 325 236 or 07407 020 470
About Feedback
Feedback plc helps clinical teams to make better decisions
faster for patients. We design products that enhance clinician
access to patient data and to their colleagues. Our unique approach
centres around individual patient episodes, into which we pull
relevant clinical data from hospital systems and around which we
build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available
to clinicians in multiple settings, in a format that enables them
to meaningfully interact with it, providing flexibility to
clinicians and free movement of patients between provider settings
- clinicians can practice from anywhere and patients can attend any
care provider for treatment.
Our products Bleepa and CareLocker work together to deliver
unparalleled value to our customers. Bleepa is our application
layer and sits on top of CareLocker as our data layer. Bleepa is a
clinician facing platform that displays clinical results from a
patient's CareLocker at a certified and regulated quality, that is
suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure,
auditable chat interface that links back to the patient medical
record. The CareLocker data storage model is built around the
patient. Our vision is one where relevant clinical data is always
available to the patient as well as to any care setting that they
may attend - a federated data architecture with the patient as the
tenant.
The Company has a number of growth opportunities domestically
and internationally across a range of markets including the NHS,
the veterinary market and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based model is
expected to provide increasing levels of revenue visibility as the
Company grows its customer base.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFVLLFXLLFFBV
(END) Dow Jones Newswires
December 19, 2023 02:00 ET (07:00 GMT)
Feedback (LSE:FDBK)
過去 株価チャート
から 2 2025 まで 3 2025
Feedback (LSE:FDBK)
過去 株価チャート
から 3 2024 まで 3 2025